/
DCF Valuation
Base-case fair value
$5.67
Intrinsic $7.56 · 25% MOS
Current price: $54.14
Base-case summary
Our base-case DCF for Travere Therapeutics, Inc. (TVTX) projects 10 years of free cash flow growth at 4.8% for years 1–5 and 2.4% for years 6–10, anchored to 4.8% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $40M in trailing free cash flow, this produces an intrinsic value of $7.56 per share. A 25% safety margin gives a fair value of $5.67, suggesting the stock is currently 90% overvalued against the $54.14 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$40M
Cash & equivalents
$209M
Total debt
$328M
Shares outstanding
92M